Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E3LP
|
|||
| Former ID |
DIB001314
|
|||
| Drug Name |
SEN-196
|
|||
| Synonyms |
EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Huntington disease [ICD-11: 8A01.10; ICD-10: G10; ICD-9: 294.1, 333.4] | Phase 2 | [1], [2] | |
| Company |
Elixir Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H13ClN2O
|
|||
| Canonical SMILES |
C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N
|
|||
| InChI |
1S/C13H13ClN2O/c14-7-4-5-11-10(6-7)8-2-1-3-9(13(15)17)12(8)16-11/h4-6,9,16H,1-3H2,(H2,15,17)
|
|||
| InChIKey |
FUZYTVDVLBBXDL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 49843-98-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7580502, 8564414, 12015946, 16240238, 26759529, 38735740, 47524531, 48268974, 51138214, 57357382, 91106622, 103472591, 104064042, 106911508, 113739208, 117703564, 118266473, 124391161, 124584355, 125333921, 126600655, 126729602, 134224869, 135698424, 136343732, 136348247, 136367542, 136920325, 136946492, 142864246, 143403468, 144115966, 162037658, 162150401, 162202713, 163134614, 163620889, 163640315, 163686210, 163687326, 164045122, 164194033, 170305960, 172131328, 175608116, 181777870, 184597282, 185989927, 202562862, 208265236
|
|||
| ChEBI ID |
CHEBI:90369
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NAD-dependent deacetylase sirtuin-1 (SIRT1) | Target Info | Inhibitor | [3], [4] |
| KEGG Pathway | FoxO signaling pathway | |||
| AMPK signaling pathway | ||||
| Glucagon signaling pathway | ||||
| Amphetamine addiction | ||||
| MicroRNAs in cancer | ||||
| Panther Pathway | p53 pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| Signaling events mediated by HDAC Class III | ||||
| E2F transcription factor network | ||||
| HIF-2-alpha transcription factor network | ||||
| Signaling events mediated by HDAC Class I | ||||
| FoxO family signaling | ||||
| Regulation of Androgen receptor activity | ||||
| Regulation of retinoblastoma protein | ||||
| Reactome | RORA activates gene expression | |||
| Regulation of HSF1-mediated heat shock response | ||||
| Circadian Clock | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8100). | |||
| REF 2 | ClinicalTrials.gov (NCT01521585) A Phase II Safety and Tolerability Study With SEN0014196. U.S. National Institutes of Health. | |||
| REF 3 | Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69. | |||
| REF 4 | Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.